Reduction of cardiotoxicity of an antitumor agent using manganes

Details Reduction of cardiotoxicity of an antitumor agent using manganes Reduction of cardiotoxicity of an antitumor agent using manganes

1998-12-17

2000-11-14

Criares, Theodore J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

514 34, 514836, A61K 3144, A61K 3170

Patent

active

061470945

ABSTRACT:
The invention relates to the use of certain chelating agents and their metal chelates and to the use of certain manganese containing compounds, in particular manganese chelates, in the manufacture of a therapeutic agent for use in reducing the cardiotoxicity of an antitumor agent. Such compounds are particularly effective in reducing the side-effects of anthracycline drugs and/or paclitaxel.

REFERENCES:
patent: 4138480 (1979-02-01), Gosalvez
Lee et al., Diss. Abst. Int(Sci.), 46(10):3396 (1986).
Carswell, JAMA, 248(31):814-819 (1982).
Brurok, Invest. Radiol., 30(3):159-167 (1995).

Affiliated with

Also associated with

Rating

Reduction of cardiotoxicity of an antitumor agent using manganes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Reduction of cardiotoxicity of an antitumor agent using manganes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reduction of cardiotoxicity of an antitumor agent using manganes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2065774